AU2003300414A8 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers - Google Patents

Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Info

Publication number: AU2003300414A8
Authority: AU; Australia
Prior art keywords: bcl; disorder; treatment; methods; antisense oligomers
Prior art date: 2002-12-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003300414A

Other versions

AU2003300414A1 (en

Inventor

Raymond P Warrell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genta Inc

Original Assignee

Genta Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-19

Filing date

2003-12-19

Publication date

2004-07-14

2003-12-16 Priority claimed from US10/738,867 external-priority patent/US7855183B2/en

2003-12-16 Priority claimed from US10/738,717 external-priority patent/US20040147473A1/en

2003-12-19 Application filed by Genta Inc filed Critical Genta Inc

2004-07-14 Publication of AU2003300414A1 publication Critical patent/AU2003300414A1/en

2004-07-14 Publication of AU2003300414A8 publication Critical patent/AU2003300414A8/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2003300414A 2002-12-19 2003-12-19 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers Abandoned AU2003300414A1 (en)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US43502902P	2002-12-19	2002-12-19
US43505702P	2002-12-19	2002-12-19
US60/435,057		2002-12-19
US60/435,029		2002-12-19
US10/738,867 US7855183B2 (en)	2000-11-10	2003-12-16	Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US10/738,867		2003-12-16
US10/738,717 US20040147473A1 (en)	2000-11-10	2003-12-16	Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US10/738,717		2003-12-16
PCT/US2003/041433 WO2004056971A2 (en)	2002-12-19	2003-12-19	Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Publications (2)

Publication Number	Publication Date
AU2003300414A1 AU2003300414A1 (en)	2004-07-14
AU2003300414A8 true AU2003300414A8 (en)	2004-07-14

Family

ID=32686284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003300414A Abandoned AU2003300414A1 (en)	2002-12-19	2003-12-19	Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Country Status (2)

Country	Link
AU (1)	AU2003300414A1 (en)
WO (1)	WO2004056971A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005067980A2 (en) *	2004-01-12	2005-07-28	Pointilliste, Inc.	Design of therapeutics and therapeutics
US8815599B2 (en)	2004-06-01	2014-08-26	Pronai Therapeutics, Inc.	Methods and compositions for the inhibition of gene expression
US20060135455A1 (en) *	2004-06-01	2006-06-22	Reza Sheikhnejad	Methods and compositions for the inhibition of gene expression
CA2631931C (en) *	2005-12-01	2014-04-29	Pronai Therapeutics, Inc.	Cancer therapies and pharmaceutical compositions used therein
EP1957044B1 (en)	2005-12-01	2013-03-13	Pronai Therapeutics, Inc.	Amphoteric liposome formulation
US20090098118A1 (en)	2007-10-15	2009-04-16	Thomas Friess	Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2010043582A1 (en) *	2008-10-17	2010-04-22	Santaris Pharma A/S	Method for the treatment of cancer
CA2890725A1 (en) *	2012-11-05	2014-05-08	Pronai Therapeutics, Inc.	Methods of using biomarkers for the treatment of cancer by modulation of bcl2\|expression
WO2017007846A1 (en)	2015-07-07	2017-01-12	Genentech, Inc.	Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
ES2965461T3 (en)	2015-08-03	2024-04-15	Biokine Therapeutics Ltd	CXCR4 inhibitor for cancer treatment
WO2022067185A1 (en) *	2020-09-27	2022-03-31	Veru Inc.	Methods of treating prostate cancer with minimal side effects

2003
- 2003-12-19 AU AU2003300414A patent/AU2003300414A1/en not_active Abandoned
- 2003-12-19 WO PCT/US2003/041433 patent/WO2004056971A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2004056971A2 (en)	2004-07-08
WO2004056971A3 (en)	2005-03-10
AU2003300414A1 (en)	2004-07-14

Publication	Publication Date	Title
IL154409A0 (en)	2003-09-17	Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
GB2382344B (en)	2003-12-10	Wastewater treatment
AU2003280004A8 (en)	2004-06-03	Hair treatment method
GB0512560D0 (en)	2005-07-27	Bioreactors for well treatment
GB0129976D0 (en)	2002-02-06	Treatment method
AU2003300414A8 (en)	2004-07-14	Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
HUP0400032A3 (en)	2012-09-28	Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
IL161005A0 (en)	2004-08-31	Neuroprotective treatment methods using selective inos inhibitors
GB0120147D0 (en)	2001-10-10	Treatment method
GB0124124D0 (en)	2001-11-28	Methods of treatment
SG89379A1 (en)	2002-06-18	Treatment apparatus
GB0105899D0 (en)	2001-04-25	Fibrosis reduction treatment
GB0130763D0 (en)	2002-02-06	Treatment methods
GB0026838D0 (en)	2000-12-20	Treatment method
GB2394656B (en)	2005-10-19	Hair treatment apparatus
EP1303281A4 (en)	2006-02-15	Methods of treatment
GB2397308B (en)	2006-11-01	Fibre treatment and conveyor apparatus
GB0126253D0 (en)	2002-01-02	Treatment method
GB0211297D0 (en)	2002-06-26	Pain treatment
GB2413798B (en)	2006-02-01	Bioreactors for well treatment
GB0130694D0 (en)	2002-02-06	Treatment
GB0102927D0 (en)	2001-03-21	Treatment method
GB0009490D0 (en)	2000-06-07	Diamond treatment
GB0115489D0 (en)	2001-08-15	Pain treatment
GB0119173D0 (en)	2001-09-26	Pain treatment

Legal Events

Date	Code	Title	Description
2005-09-22	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase